WO2001032142A1 - Cyclosporin formulation - Google Patents

Cyclosporin formulation Download PDF

Info

Publication number
WO2001032142A1
WO2001032142A1 PCT/GB2000/004143 GB0004143W WO0132142A1 WO 2001032142 A1 WO2001032142 A1 WO 2001032142A1 GB 0004143 W GB0004143 W GB 0004143W WO 0132142 A1 WO0132142 A1 WO 0132142A1
Authority
WO
WIPO (PCT)
Prior art keywords
component
preconcentrate
composition
composition according
solid
Prior art date
Application number
PCT/GB2000/004143
Other languages
French (fr)
Inventor
Yusuf Khwaja Hamied
Vinay G. Nayak
Geena Malhotra
Original Assignee
Cipla Limited
Wain, Christopher, Paul
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IN1999/000062 external-priority patent/WO2001032143A1/en
Priority claimed from GB0012816A external-priority patent/GB2362573A/en
Application filed by Cipla Limited, Wain, Christopher, Paul filed Critical Cipla Limited
Priority to EP00971598A priority Critical patent/EP1227793A1/en
Priority to AU10432/01A priority patent/AU1043201A/en
Publication of WO2001032142A1 publication Critical patent/WO2001032142A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Definitions

  • This invention relates to improved pharmaceutical compositions for the administration of water-insoluble pharmaceutically active substances especially, but not exclusively, cyclosporin.
  • EP-A-0760237 there is described a pre-concentrate microemulsion composition
  • a pre-concentrate microemulsion composition comprising a water- insoluble pharmaceutically active material; a C 8 - C 2 o fatty acid mono-, di- or tri- glyceride from a vegetable oil or any mixture of two or more thereof; and a phospholipid and another surfactant.
  • a stable oil-in-water microemulsion can be formed by mixing the preconcentrate composition with a hydrophihc phase.
  • the microemulsion compositions of EP 0760237 are made by directly dissolving the active material in the oil phase and then dispersing the oil phase in the hydrophihc phase. This has certain advantages.
  • a pharmaceutical composition in the form of a preconcentrate mixed either with a liquid hydrophihc phase to form a stable oil-in-water microemulsion or with a solid carrier to form a stable, solid blend of carrier and preconcentrate which composition is substantially free from ethanol and comprises: a) a water-insoluble pharmaceutically active material; b) one or more propylene glycol esters of a fatty acid; c) surfactant; and either d) a hydrophihc phase, wherein component (a) has been wholly directly dissolved in component (b) and component (b) is dispersed as tiny particles in component (d); or e) a solid carrier.
  • a process for making a composition according to the invention comprises dissolving component (a) in component (b) optionally with component (c), and then mixing the resulting solution either with component (d) or with component (e), and component (c) if not included earlier.
  • the method of the invention thus comprises first forming a preconcentrate by directly dissolving component (a) in component (b), the preconcentrate also containing component (c) but being free from hydrophihc phase, and then mixing the preconcentrate with the hydrophihc phase, to form a stable oil-in water microemulsion, the composition being free from ethanol.
  • the method of the invention comprises first forming a preconcentrate by directly dissolving component (a) in component (b), the preconcentrate also containing component (c), and then mixing the preconcentrate with the solid carrier, to form a solid, table composition of preconcentrate and carrier, the composition being free from ethanol.
  • the present invention therefore encompasses two different formulations of the basic preconcentrate mixture. Both of these formulations possess the advantage of increased bioavailability of the active material.
  • the invention provides a stable oil-in-water microemulsion composition wherein components (a) to (c) above have first been formed into a preconcentrate by wholly directly dissolving component (a) in component (b) optionally in the presence of component (c) (i.e. component (c) may be added later), and then mixing the preconcentrate with a hydrophihc phase.
  • the microemulsion composition is generally liquid at room temperature and can, therefore, be advantageously provided in, for example, a soft gelatine capsule or as an oral solution such as an aqueous drink, for instance.
  • the invention provides a stable, solid formulation comprising a blend of the basic preconcentrate mixture with a solid carrier.
  • the preconcentrate mixture having increased bioavailability of the active material can, for example, be formulated into a free-flowing powder which, in turn can, for instance, be put into a hard gelatin capsule or compressed into a table.
  • component (a) is a water insoluble pharmaceutically active material.
  • the invention is particularly useful with the cyclosporins, e.g. cyclosporin A. dihydrocyclosporin C, cyclosporin D and dihydrocyclosporin D. It is also useful with other water-insoluble substances such as, for example, water-insoluble peptides, or water-insoluble antimicrobial or antineoplastic substances. Examples include desmopresin, calcitonin, insulin, lenprolide, erythropoetin, a cephalosporin, vincristine, vinblastine, taxol, etoposide or mixtures thereof.
  • component (a) is in solution in component (b).
  • Component (b) can be a propylene glycol ester of a fatty acid or a mixture of any two or more such esters.
  • the fatty acids may optionally be derived from a vegetable oil and are preferably C 8 - C 20 residues.
  • Particular preferred compounds are propylene glycol monocaprylate (Caprgol 90) and propylene glycol monolaurate (Lauroglycol 90).
  • Caprgol 90 propylene glycol monocaprylate
  • Liauroglycol 90 propylene glycol monolaurate
  • oleoyl macrogol-6 glycerides (Labrafil M 1944 CS), linoleoyl macrogol-6 glycerides (Labrafil M 2125 CS), and caprylocaproyl macrogol-8 glycerides (Labrasol) are particularly preferred compounds for use with the oils employed in the present invention.
  • Component (c) is a surfactant to provide the preconcentrate mixture and, where employed, the fully formed microemulsion with stability.
  • surfactants which can be used, but we prefer to use polyoxyl 40 hydrogenated castor oil, polyoxyethylene-sorbitan monooleate, polyoxyethylene-sorbitan monopalmitate, polyoxyethylene-sorbitan monolaurate or polyoxyethylene sorbitan monostearate.
  • the surfactant can be mixed with a phospholipid, such as lecithin.
  • a weight ratio of component (a) to surfactant of about 1 :1 to about 1 :50, but ratios outside this range can also be employed if desired.
  • a phospholipid is included in the composition, we prefer to use a weight ratio of component (a) to phospholipid of about 1 :05 to about 1 :5.0, but, again, other ratios can be used.
  • component (d) is a hydrophihc phase.
  • the preferred material is propylene glycol or diethylene glycol monoethyl ether (transcutol) but other substances can be used. Ethanol cannot be present. Water can of course also be present but it is not preferred.
  • propylene glycol component (a) remains wholly dissolved in the oil phase (component (b)).
  • Microemulsions are transparent due to the very small particle size of the dispersed phase, typically less than 200 nm. Such small droplets produce only weak scattering of visible light when compared with that from the coarse droplets (1 -10 nm) of normal emulsions.
  • An essential difference between microemulsions and emulsions is that microemulsions form spontaneously and, unlike emulsions, required little mechanical work in their formulation.
  • General reviews on microemulsions are provided by Attwood D. et al J. Colloid Interface Sci 46:249 and Kahlweit M. et al J. Colloid Interface Sci 118:436.
  • microemulsions can be formed by diluting with aqueous liquid (e.g. water, fruit juice, milk etc.) to form an oil-in-water microemulsion, e.g. for oral administration.
  • aqueous liquid e.g. water, fruit juice, milk etc.
  • the role played by bile salts in the initial step of fragmentation of fat globules, essential for fat digestion, is circumvented.
  • the rate determining factor for the absorption of drug in the vehicle is not the enzymatic metabolism of triglycerides but rests primarily in the breakdown of the fat globules into micro particles since the enzymes (lipases) act mainly at the surface of the fat globules.
  • the weight percent of hydrophilic phase is generally up to about 75%, most usually from 15 to 50%, and preferably from 35 to 50%.
  • component (e) is employed instead of component (d).
  • Preferred solid carriers include colloidal silicon dioxide and polyvinyl pyrrolidone (cross Povidone) but other suitable inert solid substances can also be used, as will be clear to those skilled in the art.
  • the solid carrier will be in the form of a dry powder.
  • the preconcentrate mixture (comprising active material, oil and surfactant) is simply blended with the solid material such that the oily preconcentrate is absorbed by the material.
  • the blended mixture is provided in the form of a free-flowing powder.
  • Such a powder can then be easily coated, for example, into a hard gelatin capsule or, alternatively, compressed into tablets, for instance.
  • the technique of absorbing an oily phase (in this case an oily preconcentrate) on to a solid phase such as colloidal silicon dioxide followed by formulation into a final dosage form is a technique well known by those skilled in the art of formulation, so further details are considered unnecessary.
  • Both the microemulsion and solid compositions can consist only of the components described, or they can contain other substances.
  • an antioxidant e.g. D- to copherol can be used.
  • Propyl gallate may be used as an alternative.
  • compositions comprising a blend of preconcentrate and solid carrier are:
  • Glyceryl Monolinoleate (Maisine 33-1) 17.25 Propylene glycol monocaprylate
  • the blended preparations were made as follows:
  • Microemulsions of the invention were made of the compositions indicated, by dissolving the cyclosporin A in the oils and then forming the oil-in- water emulsions. The procedure was:
  • the oral solution which is filled into bottles can be administered using a syringe or more preferably with the aid of a metered dose pump with a dropper actuator.
  • compositions described in Examples 4 to 8 were subjected to stability examinations under accelerated conditions of temperature and humidity.
  • the solutions were stored at RT (25°C ⁇ 2°C). Ref 40°C-80% RH and 45°C, after filling into flint glass vials.

Abstract

A pharmaceutical composition in the form of a preconcentrate mixed either with a liquid hydrophilic phase to form a stable oil-in-water microemulsion or with a solid carrier to form a stable, solid blend of carrier and preconcentrate, comprises a) a water-insoluble pharmaceutically active material; b) one or more propylene glycol esters of a fatty acid; c) surfactant; and either d) a hydrophilic phase, wherein component (a) has been wholly directly dissolved in component (b) and component (b) is dispersed as tiny particles in component (d); or e) a solid carrier. The composition is substantially free from ethanol.

Description

CYCLOSPORIN FORMULATION
This invention relates to improved pharmaceutical compositions for the administration of water-insoluble pharmaceutically active substances especially, but not exclusively, cyclosporin.
In our European patent specification no. EP-A-0760237 there is described a pre-concentrate microemulsion composition comprising a water- insoluble pharmaceutically active material; a C8 - C2o fatty acid mono-, di- or tri- glyceride from a vegetable oil or any mixture of two or more thereof; and a phospholipid and another surfactant. A stable oil-in-water microemulsion can be formed by mixing the preconcentrate composition with a hydrophihc phase. Unlike prior art microemulsion compositions, the microemulsion compositions of EP 0760237 are made by directly dissolving the active material in the oil phase and then dispersing the oil phase in the hydrophihc phase. This has certain advantages. For example, in the case of cyclosporin microemulsions, it eliminates or vastly reduces the tendency for solid microfine cyclosporin to be precipitated during use of the microemulsions, a problem encountered with many of the prior art microemulsions. Whilst the microemulsions disclosed in EP-A-0760237 are generally very satisfactory in many ways, we have found that there is an upper limit to the bioavailability of the active material in the compositions of EP-A-0760237. We have now discovered that by judiciously alternating the components of the oil phase in the compositions of EP-A-0760237, the bioavailability of the active material can, suφrisingly, be increased. The present compositions thus possess the advantages of the compositions of EP-A-0760237 together with, in addition, the advantage of increased bioavailability of the active material.
According to the present invention, there is provided a pharmaceutical composition in the form of a preconcentrate mixed either with a liquid hydrophihc phase to form a stable oil-in-water microemulsion or with a solid carrier to form a stable, solid blend of carrier and preconcentrate, which composition is substantially free from ethanol and comprises: a) a water-insoluble pharmaceutically active material; b) one or more propylene glycol esters of a fatty acid; c) surfactant; and either d) a hydrophihc phase, wherein component (a) has been wholly directly dissolved in component (b) and component (b) is dispersed as tiny particles in component (d); or e) a solid carrier.
There is also provided a process for making a composition according to the invention, which process comprises dissolving component (a) in component (b) optionally with component (c), and then mixing the resulting solution either with component (d) or with component (e), and component (c) if not included earlier.
In the case of a microemulsion, the method of the invention thus comprises first forming a preconcentrate by directly dissolving component (a) in component (b), the preconcentrate also containing component (c) but being free from hydrophihc phase, and then mixing the preconcentrate with the hydrophihc phase, to form a stable oil-in water microemulsion, the composition being free from ethanol.
In the case of a solid composition, the method of the invention comprises first forming a preconcentrate by directly dissolving component (a) in component (b), the preconcentrate also containing component (c), and then mixing the preconcentrate with the solid carrier, to form a solid, table composition of preconcentrate and carrier, the composition being free from ethanol.
In its broadest aspect, the present invention therefore encompasses two different formulations of the basic preconcentrate mixture. Both of these formulations possess the advantage of increased bioavailability of the active material.
Thus, in a first aspect, the invention provides a stable oil-in-water microemulsion composition wherein components (a) to (c) above have first been formed into a preconcentrate by wholly directly dissolving component (a) in component (b) optionally in the presence of component (c) (i.e. component (c) may be added later), and then mixing the preconcentrate with a hydrophihc phase. The microemulsion composition is generally liquid at room temperature and can, therefore, be advantageously provided in, for example, a soft gelatine capsule or as an oral solution such as an aqueous drink, for instance.
In a second aspect, the invention provides a stable, solid formulation comprising a blend of the basic preconcentrate mixture with a solid carrier. In this way, the preconcentrate mixture having increased bioavailability of the active material can, for example, be formulated into a free-flowing powder which, in turn can, for instance, be put into a hard gelatin capsule or compressed into a table. We generally prefer to formulate the composition of the invention in this way rather than as a microemulsion, since the solid formulation is simple to process and has excellent stability.
In the present invention, component (a) is a water insoluble pharmaceutically active material. The invention is particularly useful with the cyclosporins, e.g. cyclosporin A. dihydrocyclosporin C, cyclosporin D and dihydrocyclosporin D. It is also useful with other water-insoluble substances such as, for example, water-insoluble peptides, or water-insoluble antimicrobial or antineoplastic substances. Examples include desmopresin, calcitonin, insulin, lenprolide, erythropoetin, a cephalosporin, vincristine, vinblastine, taxol, etoposide or mixtures thereof.
In the compositions of the invention, component (a) is in solution in component (b). Component (b) can be a propylene glycol ester of a fatty acid or a mixture of any two or more such esters. The fatty acids may optionally be derived from a vegetable oil and are preferably C8 - C20 residues. Particular preferred compounds are propylene glycol monocaprylate (Caprgol 90) and propylene glycol monolaurate (Lauroglycol 90). We prefer to formulate the composition such that the weight ratio of component (a) to component (b) is from about 1 : 1 to about 1 : 10 but ratios outside this range can be used if desired.
These compounds, which increase the bioavailability of the active material can be used alone or in combination with one or more of the glycerides described in EP 0760237. For example, oleoyl macrogol-6 glycerides (Labrafil M 1944 CS), linoleoyl macrogol-6 glycerides (Labrafil M 2125 CS), and caprylocaproyl macrogol-8 glycerides (Labrasol) are particularly preferred compounds for use with the oils employed in the present invention.
Component (c) is a surfactant to provide the preconcentrate mixture and, where employed, the fully formed microemulsion with stability. Those skilled in the art will be aware of many surfactants which can be used, but we prefer to use polyoxyl 40 hydrogenated castor oil, polyoxyethylene-sorbitan monooleate, polyoxyethylene-sorbitan monopalmitate, polyoxyethylene-sorbitan monolaurate or polyoxyethylene sorbitan monostearate. If desired, the surfactant can be mixed with a phospholipid, such as lecithin. We prefer to use a weight ratio of component (a) to surfactant of about 1 :1 to about 1 :50, but ratios outside this range can also be employed if desired. When a phospholipid is included in the composition, we prefer to use a weight ratio of component (a) to phospholipid of about 1 :05 to about 1 :5.0, but, again, other ratios can be used.
In the case where the composition of the invention is provided as a microemulsion, component (d) is a hydrophihc phase. The preferred material is propylene glycol or diethylene glycol monoethyl ether (transcutol) but other substances can be used. Ethanol cannot be present. Water can of course also be present but it is not preferred. Despite the use of propylene glycol, component (a) remains wholly dissolved in the oil phase (component (b)).
Microemulsions are transparent due to the very small particle size of the dispersed phase, typically less than 200 nm. Such small droplets produce only weak scattering of visible light when compared with that from the coarse droplets (1 -10 nm) of normal emulsions. An essential difference between microemulsions and emulsions is that microemulsions form spontaneously and, unlike emulsions, required little mechanical work in their formulation. General reviews on microemulsions are provided by Attwood D. et al J. Colloid Interface Sci 46:249 and Kahlweit M. et al J. Colloid Interface Sci 118:436.
The microemulsions can be formed by diluting with aqueous liquid (e.g. water, fruit juice, milk etc.) to form an oil-in-water microemulsion, e.g. for oral administration. This aids in ready absorption as the surface area of the fat globules is largely increased. The role played by bile salts in the initial step of fragmentation of fat globules, essential for fat digestion, is circumvented.
The rate determining factor for the absorption of drug in the vehicle is not the enzymatic metabolism of triglycerides but rests primarily in the breakdown of the fat globules into micro particles since the enzymes (lipases) act mainly at the surface of the fat globules.
In the microemulsions of the invention, the amounts of the components, in percent by weight, are as follows: Component General Usual Preferred
Active pharmaceutical 1-12% 2.5-10% 7 -1 0% Oil phase 20-80% 30-60% 25-40%
Surfactant 20-40%o 25-60% 40-50%
Hydrophilic phase 10-60% 20-50% 25-30%
In the microemulsions, the weight percent of hydrophilic phase is generally up to about 75%, most usually from 15 to 50%, and preferably from 35 to 50%.
In the case where the composition of the present invention is provided as a blend of preconcentrate and solid carrier, component (e) is employed instead of component (d). Preferred solid carriers include colloidal silicon dioxide and polyvinyl pyrrolidone (cross Povidone) but other suitable inert solid substances can also be used, as will be clear to those skilled in the art. Typically, the solid carrier will be in the form of a dry powder. Generally, the preconcentrate mixture (comprising active material, oil and surfactant) is simply blended with the solid material such that the oily preconcentrate is absorbed by the material. Preferably, the blended mixture is provided in the form of a free-flowing powder. Such a powder can then be easily coated, for example, into a hard gelatin capsule or, alternatively, compressed into tablets, for instance. The technique of absorbing an oily phase (in this case an oily preconcentrate) on to a solid phase such as colloidal silicon dioxide followed by formulation into a final dosage form is a technique well known by those skilled in the art of formulation, so further details are considered unnecessary.
Both the microemulsion and solid compositions can consist only of the components described, or they can contain other substances. For example, in order to prevent oxidation/ rancidification of the natural oils, an antioxidant, e.g. D- to copherol can be used. Propyl gallate may be used as an alternative.
In order that the invention may be more fully understood, the following examples are given by way of illustration only. Examples 1-3
Examples of compositions comprising a blend of preconcentrate and solid carrier are: Example 1 Imusporin-25
Component mg/capsule
Cyclosporin USP 25
Glyceryl Monolinoleate (Maisine 33-1) 17.25 Propylene glycol monocaprylate
17.25 (Capryol 90)
Polyoxyl 35 Castor Oil NF (Cremophor
50.00 EL)
Colloidal silicon dioxide 52.50
Crospovidone USP (P VP CL-M) 13.00
Net Fill Wt/cap (mg) 175.00
Example 2
Imusporin-50
Component mg/capsule
Cyclosporin USP 50.00
Glyceryl Monolinoleate (Maisine 33-1) 34.50
Propylene glycol monocaprylate
34.50
(Capryol 90)
Polyoxyl 35 Castor Oil NF (Cremophor
100.00
EL)
Colloidal silicon dioxide 105.00
Crospovidone USP (PVP CL-M) 26.00
Net Fill Wt/cap (mg) 350.00 Example 3
Imusporin-100
Component mg/capsule
Cyclosporin USP 100.00
Glyceryl Monolinoleate (Maisine 33-1) 69.00
Propylene glycol monocaprylate
69.00 (Capryol 90)
Polyoxyl 35 Castor Oil NF (Cremophor
200.00
EL)
Colloidal silicon dioxide 210.00
Crospovidone USP (PVP CL-M) 52.00
Net Fill Wt/cap (mg) 700.00
The blended preparations were made as follows:
1 Mix Maisine 35-1, Capryol 90 and Cremophor EL in a clean jacketed vessel.
2 Add Cyclosporin to the above vessel under stirring, continue stirring for about 70-75 mins. If required, heat the blend to not more than 50°C till the drug dissolves completely.
4 Cool the above blend to room temperature and strain through 150#.
5 Sift Aerosil and Crospovidone through 20# and 40# respectively. Mix in a suitable mixer.
6 Adsorb the above blend (step 4) over the mixture of Aerosil and Crospovidone.
7 Pass the powder blend of Cyclosporin through 20#.
8 Fill this blend in hard gelatin capsules or compressed with tablets.
The blends were then either fill into hard gelatin capsules or compressed into tablets. Examples 4 - 8
Microemulsions of the invention were made of the compositions indicated, by dissolving the cyclosporin A in the oils and then forming the oil-in- water emulsions. The procedure was:
(a) dissolve the cyclosporin A in the mixture of oils with slight warming and under stirring to obtain a clear yellow liquid. Confirm the complete dissolution of the drug by microscopy.
(b) add the surfactant with stirring.
(c) add the hydrophilic phase ; with stirring
(d) add the alpho tocopherol and mix thoroughly.
Example 4
Preparation of microemulsion for administration in Soft Gelatin capsules:
Component mg/capsule
Capryol 90 130
Castor oil 130
Polyoxyl-40 hydrogenated 400
Castor oil - α-tocopherol 10
Propylene gl ycol 200
Cyclosporin A 100
Example 5
Preparation of microemulsion for administration as oral solution: Component mg/capsule
Capryol 90 150
Maisine 125 Polysorbate-80 49
(Tween 80) α-tocopherol 10
Transcutol 225
Cyclosporin A 100
Example 6
Preparation of microemulsion for administration as oral solution
Component mg/capsule
Capryol 90 275
Polyoxyl-40 hydrogenated castor oil 425 α-tocopherol 10
Propylene glycol 225
Cyclosporin A 100
Example 7
Preparation of microemulsion for administration as oral solution:
Component %
Capryol 90 130
Lauroglycol 90 130
Polysorbate 80 (Tween 80) 400 α-tocopherol 10
Propylene glycol 200
Cyclosporin A 100
Example 8
Preparation of microemulsion for administration as oral solution: Component mg/capsule
Capryol 90 14
Maisine 15
Polyoxyl-40 hydrogenated castor oil 45 α-tocopherol 1
Transcutol 25
Cyclosporin A 10
The oral solution which is filled into bottles can be administered using a syringe or more preferably with the aid of a metered dose pump with a dropper actuator.
The compositions described in Examples 4 to 8 were subjected to stability examinations under accelerated conditions of temperature and humidity. The solutions were stored at RT (25°C ± 2°C). Ref 40°C-80% RH and 45°C, after filling into flint glass vials.
Simultaneously with the examination of solutions prepared according to the process of the invention, the stability of the commercially available Neoral capsules containing lOOmg cyclosporin A per capsule was also examined. It was observed from the above examination that the stability of solutions prepared according to the process of invention did not differ from the stability of the commercially available composition.

Claims

CLAIMS:
1. A pharmaceutical composition in the form of a preconcentrate mixed either with a liquid hydrophilic phase to form a stable oil-in-water microemulsion or with a solid carrier to form a stable, solid blend of carrier and preconcentrate, which composition is substantially free from ethanol and comprises: a) a water-insoluble pharmaceutically active material; b) one or more propylene glycol esters of a fatty acid; c) surfactant; and either d) a hydrophilic phase, wherein component (a) has been wholly directly dissolved in component (b) and component (b) is dispersed as tiny particles in component (d); or e) a solid carrier.
2. A composition according to claim 1, which composition is a microemulsion comprising components (a), (b), (c) and (d).
3. A composition according to claim 1, which composition is a blend of said preconcentrate and said solid carrier comprising components (a), (b), (c) and (e).
4. A composition according to claim 1, 2 or 3, wherein component (a) is a cyclosporin, or another water-insoluble peptide, or a water-insoluble antimicrobial or antineoplastic substance or mixtures thereof.
5. A composition according to claim 4, wherein component (a) is cyclosporin A, dihydrocyclosporin C, cyclosporin D or dihydrocyclosporin D, or desmopresin, calcitonin, insulin, leuprolide, erythropoetin, a cephalosporin, vincristine, vinblastine, taxol or etoposide or mixtures thereof.
6. A composition according to any preceding claim, wherein component (b) is a propylene glycol ester of Cι2 to C! fatty acids.
7. A composition according to any preceding claim, wherein said surfactant is polyoxyl 40 hydrogenated castor oil, polyoxyethylene-sorbitan monooleate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene-sorbitan monolaurate or polyoxyethylene-sorbitan monostearate or mixtures thereof.
8. A composition according to any preceding claim, wherein component (c) further comprises a phospholipid.
9. A composition according to any preceding claim, wherein the weight ratio of component (a) to component (b) is from 1:1 to 1 :10.
10. A composition according to claim 8 or 9, wherein the weight ratio of component (a) to said phospholipid is from 1 :0.5 to 1 :5.0.
11. A composition according to any preceding claim, wherein the weight ratio of component (a) to said surfactant is from 1 :1 to 1 :5.0.
12. A composition according to any of claims 1-9 and containing component (e), wherein component (e) is colloidal silicon dioxide, polyvinyl pyrrolidone or a mixture thereof.
13. A soft gelatin capsule or oral administration fluid which comprises a composition as claimed in any of claims 1 to 11
14. A tablet or hard gelatin capsule which comprises a composition as claimed in any of claims 1 to 12 when in said solid form.
15. A process for making a composition according to claim 1, which comprises dissolving component (a) in component (b) optionally with component (c), and then mixing the resulting solution either with component (d) or with component (e) and component (c) if not included earlier.
16. A process according to claim 150, wherein a preconcentrate composition is mixed with component (d).
17. A process according to claim 15, wherein a preconcentrate composition is mixed with component (e).
18. A method of making a pharmaceutical composition according to any of claims 1 to 11, which method comprises first forming a preconcentrate by directly dissolving component (a) in component (b), the preconcentrate also containing component (c) but being free from hydrophilic phase, and then mixing the preconcentrate with the hydrophilic phase, to form said stable oil-in-water microemulsion, the composition being free from ethanol.
19. A method of making a pharmaceutical composition according to any of claims 1-12, which method comprises first forming a preconcentrate by directly dissolving component (a) in component (b), the preconcentrate also containing component (c), and then mixing the preconcentrate with the solid carrier, to form a solid, stable composition if preconcentrated and carrier, the composition being free from ethanol.
PCT/GB2000/004143 1999-11-02 2000-10-27 Cyclosporin formulation WO2001032142A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00971598A EP1227793A1 (en) 1999-11-02 2000-10-27 Cyclosporin formulation
AU10432/01A AU1043201A (en) 1999-11-02 2000-10-27 Cyclosporin formulation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/IN1999/000062 WO2001032143A1 (en) 1999-11-02 1999-11-02 A pharmaceutical composition for the administration of water-insoluble pharmaceutically active substances and a process for preparation thereof
INPCT/IN99/00062 1999-11-02
GB0012816A GB2362573A (en) 2000-05-25 2000-05-25 Cyclosporin formulation
GB0012816.5 2000-05-25

Publications (1)

Publication Number Publication Date
WO2001032142A1 true WO2001032142A1 (en) 2001-05-10

Family

ID=26244360

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/004143 WO2001032142A1 (en) 1999-11-02 2000-10-27 Cyclosporin formulation

Country Status (3)

Country Link
EP (1) EP1227793A1 (en)
AU (1) AU1043201A (en)
WO (1) WO2001032142A1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501208A (en) * 2002-08-02 2006-01-12 パテル、サティシュチャンドラ・プナンバイ A pharmaceutical composition containing cyclosporine, propylene glycol ester and nonionic surfactant for oral administration.
WO2006021709A2 (en) * 2004-08-05 2006-03-02 Gattefosse Holding Anhydrous solid particle containing a lipid composition and pharmaceutical composition containing said particles
WO2006085217A2 (en) * 2005-02-08 2006-08-17 Pfizer Products Inc. Solid adsorbates of hydrophobic drugs
WO2007016073A1 (en) * 2005-07-27 2007-02-08 Allergan, Inc. Pharmaceutical emulsion compositions comprising cyclosporin
EP1767193A3 (en) * 2000-04-10 2009-01-28 Novartis AG Pharmaceutical compositions
JP2010120930A (en) * 2008-10-22 2010-06-03 Santen Pharmaceut Co Ltd Pharmaceutical composition improving absorbability through intestinal tract
US8501174B2 (en) 2005-10-14 2013-08-06 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US9248191B2 (en) 2003-09-15 2016-02-02 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US9278070B2 (en) 2009-05-18 2016-03-08 Sigmoid Pharma Limited Composition comprising oil drops
US9320746B2 (en) 2013-02-21 2016-04-26 Sigmoid Pharma Limited Method for treating intestinal fibrosis
US9387179B2 (en) 2007-04-04 2016-07-12 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
US9821024B2 (en) 2010-11-25 2017-11-21 Sigmoid Pharma Limited Immunomodulatory compositions
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US9878036B2 (en) 2009-08-12 2018-01-30 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
US10993987B2 (en) 2014-11-07 2021-05-04 Sublimity Therapeutics Limited Compositions comprising Cyclosporin

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2222770A (en) * 1988-09-16 1990-03-21 Sandoz Ltd Cyclosporin emulsion compositions
US5543393A (en) * 1994-02-25 1996-08-06 Chong Kun Dang Corp. Cyclosporin containing powder composition
EP0760237A1 (en) * 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
WO1998040051A1 (en) * 1997-03-12 1998-09-17 Abbott Laboratories Lipophilic binary systems for the administration of lipophilic compounds
WO1999044584A1 (en) * 1998-03-06 1999-09-10 Novartis Ag Emulsion preconcentrates containing cyclosporin or a macrolide

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2222770A (en) * 1988-09-16 1990-03-21 Sandoz Ltd Cyclosporin emulsion compositions
US5543393A (en) * 1994-02-25 1996-08-06 Chong Kun Dang Corp. Cyclosporin containing powder composition
EP0760237A1 (en) * 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
WO1998040051A1 (en) * 1997-03-12 1998-09-17 Abbott Laboratories Lipophilic binary systems for the administration of lipophilic compounds
WO1999044584A1 (en) * 1998-03-06 1999-09-10 Novartis Ag Emulsion preconcentrates containing cyclosporin or a macrolide

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1767193A3 (en) * 2000-04-10 2009-01-28 Novartis AG Pharmaceutical compositions
JP2006501208A (en) * 2002-08-02 2006-01-12 パテル、サティシュチャンドラ・プナンバイ A pharmaceutical composition containing cyclosporine, propylene glycol ester and nonionic surfactant for oral administration.
US9248191B2 (en) 2003-09-15 2016-02-02 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
WO2006021709A2 (en) * 2004-08-05 2006-03-02 Gattefosse Holding Anhydrous solid particle containing a lipid composition and pharmaceutical composition containing said particles
WO2006021709A3 (en) * 2004-08-05 2006-10-12 Gattefosse Holding Anhydrous solid particle containing a lipid composition and pharmaceutical composition containing said particles
WO2006085217A2 (en) * 2005-02-08 2006-08-17 Pfizer Products Inc. Solid adsorbates of hydrophobic drugs
WO2006085217A3 (en) * 2005-02-08 2006-09-28 Pfizer Prod Inc Solid adsorbates of hydrophobic drugs
US8906861B2 (en) 2005-07-27 2014-12-09 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
WO2007016073A1 (en) * 2005-07-27 2007-02-08 Allergan, Inc. Pharmaceutical emulsion compositions comprising cyclosporin
US7501393B2 (en) 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US8501174B2 (en) 2005-10-14 2013-08-06 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US10434139B2 (en) 2007-04-04 2019-10-08 Sublimity Therapeutics Limited Oral pharmaceutical composition
US9387179B2 (en) 2007-04-04 2016-07-12 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
US9585844B2 (en) 2007-04-04 2017-03-07 Sigmoid Pharma Limited Oral pharmaceutical composition
US9675558B2 (en) 2007-04-04 2017-06-13 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
US10434140B2 (en) 2007-04-04 2019-10-08 Sublimity Therapeutics Limited Pharmaceutical cyclosporin compositions
JP2010120930A (en) * 2008-10-22 2010-06-03 Santen Pharmaceut Co Ltd Pharmaceutical composition improving absorbability through intestinal tract
US9999651B2 (en) 2009-05-18 2018-06-19 Sigmoid Pharma Limited Composition comprising oil drops
US9278070B2 (en) 2009-05-18 2016-03-08 Sigmoid Pharma Limited Composition comprising oil drops
US9878036B2 (en) 2009-08-12 2018-01-30 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
US9821024B2 (en) 2010-11-25 2017-11-21 Sigmoid Pharma Limited Immunomodulatory compositions
US9980902B2 (en) 2013-02-21 2018-05-29 Sigmoid Pharma Limited Method for treating intestinal fibrosis
US9320746B2 (en) 2013-02-21 2016-04-26 Sigmoid Pharma Limited Method for treating intestinal fibrosis
US10993987B2 (en) 2014-11-07 2021-05-04 Sublimity Therapeutics Limited Compositions comprising Cyclosporin

Also Published As

Publication number Publication date
AU1043201A (en) 2001-05-14
EP1227793A1 (en) 2002-08-07

Similar Documents

Publication Publication Date Title
US5929030A (en) Pharmaceutical compositions
KR101759750B1 (en) Self micro―emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof
US7799340B2 (en) Pharmaceutical compositions for lipophilic drugs
JP4761093B2 (en) Pharmaceutical composition comprising omega-3 fatty acid oil
KR100541198B1 (en) Microemulsion Spare Concentrate
EP2062571B1 (en) Self-emulsifying pharmaceutical composition with enhanced bioavailability
US6432445B1 (en) Pharmaceutical capsules comprising a cyclosporin
JP2011105754A (en) Hydrophilic binary systems for administration of cyclosporine
US8252326B2 (en) Self-microemulsifying dosage forms of low solubility active ingredients such as co-enzyme Q10
EP1227793A1 (en) Cyclosporin formulation
JP2005516959A (en) Microemulsion preconcentrate
AU777740B2 (en) Pharmaceutical compositions for oral and topical administration
TWI599368B (en) Capsule for oral administration comprising pharmaceutical composition alisporivir
EP1151755B1 (en) Pharmaceutical compositions comprising cyclosporin as active ingredient
JP2006509785A (en) Oral microemulsion composition of biphenyldimethyldicarboxylic acid
GB2362573A (en) Cyclosporin formulation
WO2001032143A1 (en) A pharmaceutical composition for the administration of water-insoluble pharmaceutically active substances and a process for preparation thereof
EP0431659B1 (en) Pharmaceutical compositions of tebufelone
WO2004073693A1 (en) Soft capsule containing cyclosporine and it's manufacturing process
JP2005255677A (en) Cyclosporine preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000971598

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000971598

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000971598

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP